Recent developments in areas important to cardiac surgeons once more underscore the ATS Medical commitment to setting higher standards in selectively added cardiac surgery-focused products and services.
At the Forefront of the Emerging Field of Less-invasive and Minimally-invasive Heart Tissue Valve Replacement
It is believed that future substantial growth in the heart valve industry will come with the introduction of timesaving, minimally-invasive products and procedures. ATS Medical is currently developing a number of aortic valve concepts in response to this.
|
The ATS 3f Enable™ Aortic Heart Valve, currently in clinical studies, is designed to reduce surgical cross-clamp and cardio-pulmonary bypass time without compromising product performance or patient safety. It utilizes only a single guiding suture at implantation and requires less than two minutes for insertion. It is part of the continuing evolution of the ATS 3f® Aortic Bioprosthesis design series.
|
ATS 3f Enable™ Aortic Heart Valve
|
|
|
The ATS 3f Entrata™ Aortic Valve System is minimally invasive with transapical and percutaneous delivery and is meant for elimination of heart and lung bypass machine time during heart valve replacement. It is further articulation within the ATS 3f® Bioprosthesis design series.
|
ATS 3f Entrata™ Aortic Valve System
|
|
Uniquely positioned and conforming with an evolutionary strategy, both technologies are expected to firmly establish ATS Medical as a leader in the less invasive and minimally invasive heart valve replacement market.
|